Stocks
Allergan Financial Statements (AGN) |
||||||||||
| Allergansmart-lab.ru | % | 2015 | 2016 | 2017 | 2018 | 2019 | LTM ? | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Report date | 26.02.2016 | 24.02.2017 | 16.02.2018 | 15.02.2019 | 18.02.2020 | 07.05.2020 | ||||
| Currency | USD | USD | USD | USD | USD | USD | ||||
| Financial report URL | ||||||||||
| Revenue, bln rub | ? | 12 688 | 14 571 | 15 941 | 15 787 | 16 089 | 16 096 | |||
| Operating Income, bln rub | -3 131 | -1 826 | -5 975 | -6 049 | -4 446 | -3 436 | ||||
| EBITDA, bln rub | ? | 9 542 | 21 003 | -2 332 | 792.7 | 1 719 | 2 716 | |||
| Net profit, bln rub | ? | 3 915 | 14 973 | -4 126 | -5 096 | -5 271 | -2 485 | |||
| OCF, bln rub | ? | 4 606 | 1 446 | 6 079 | 5 640 | 7 239 | 6 121 | |||
| CAPEX, bln rub | ? | 454.9 | 331.4 | 349.9 | 253.5 | 375.0 | 370.9 | |||
| FCF, bln rub | ? | 4 151 | 1 114 | 5 729 | 5 387 | 6 864 | 5 750 | |||
| Dividend payout, bln rub | 208.1 | 278.4 | 1 218 | 1 050 | 974.4 | 971.8 | ||||
| Ordinary share dividend yield, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||||
| Dividend payout ratio, % | 5.32% | 1.86% | 0.00% | 0.00% | 0.00% | -39.1% | ||||
| OPEX, bln rub | 13 067 | 14 535 | 19 748 | 19 645 | 18 099 | 16 947 | ||||
| Cost of production, bln rub | 2 752 | 1 861 | 2 168 | 2 191 | 2 435 | 2 584 | ||||
| R&D, bln rub | 2 359 | 2 576 | 2 100 | 2 266 | 1 812 | 1 807 | ||||
| Interest expenses, bln rub | 1 193 | 1 296 | 1 096 | 911.2 | 783.0 | 765.8 | ||||
| Assets, bln rub | 135 583 | 128 986 | 118 342 | 101 788 | 94 699 | 88 426 | ||||
| Net Assets, bln rub | ? | 76 591 | 76 193 | 73 821 | 65 114 | 58 174 | 57 998 | |||
| Debt, bln rub | 42 530 | 32 769 | 30 075 | 23 798 | 22 649 | 19 550 | ||||
| Cash, bln rub | 1 105 | 13 226 | 6 449 | 1 907 | 5 915 | 2 618 | ||||
| Net debt, bln rub | 41 425 | 19 543 | 23 626 | 21 890 | 16 734 | 16 931 | ||||
| Ordinary share price, rub | 312.5 | 210.0 | 163.6 | 133.7 | 191.2 | 193.0 | ||||
| Number of ordinary shares, mln | 367.8 | 384.9 | 333.8 | 337.0 | 329.0 | 331.9 | ||||
| Market cap, bln rub | 114 938 | 80 833 | 54 603 | 45 043 | 62 895 | 64 070 | ||||
| EV, bln rub | ? | 156 363 | 100 376 | 78 229 | 66 934 | 79 629 | 81 001 | |||
| Book value, bln rub | -37 710 | -32 782 | -30 690 | -24 495 | -21 965 | -19 498 | ||||
| EPS, rub | ? | 10.6 | 38.9 | -12.4 | -15.1 | -16.0 | -7.49 | |||
| FCF/share, rub | 11.3 | 2.90 | 17.2 | 16.0 | 20.9 | 17.3 | ||||
| BV/share, rub | -102.5 | -85.2 | -91.9 | -72.7 | -66.8 | -58.7 | ||||
| EBITDA margin, % | ? | 75.2% | 144.1% | -14.6% | 5.02% | 10.7% | 16.9% | |||
| Net margin, % | ? | 30.9% | 102.8% | -25.9% | -32.3% | -32.8% | -15.4% | |||
| FCF yield, % | ? | 3.61% | 1.38% | 10.5% | 12.0% | 10.9% | 8.98% | |||
| ROE, % | ? | 5.11% | 19.7% | -5.59% | -7.83% | -9.06% | -4.28% | |||
| ROA, % | ? | 2.89% | 11.6% | -3.49% | -5.01% | -5.57% | -2.81% | |||
| P/E | ? | 29.4 | 5.40 | -13.2 | -8.84 | -11.9 | -25.8 | |||
| P/FCF | 27.7 | 72.5 | 9.53 | 8.36 | 9.16 | 11.1 | ||||
| P/S | ? | 9.06 | 5.55 | 3.43 | 2.85 | 3.91 | 3.98 | |||
| P/BV | ? | -3.05 | -2.47 | -1.78 | -1.84 | -2.86 | -3.29 | |||
| EV/EBITDA | ? | 16.4 | 4.78 | -33.6 | 84.4 | 46.3 | 29.8 | |||
| Debt/EBITDA | 4.34 | 0.93 | -10.1 | 27.6 | 9.73 | 6.23 | ||||
| R&D/CAPEX, % | 518.5% | 777.2% | 600.2% | 894.0% | 483.2% | 487.2% | ||||
| CAPEX/Revenue, % | 3.59% | 2.27% | 2.20% | 1.61% | 2.33% | 2.30% | ||||
| Allergan shareholders | ||||||||||
